ErbaLisa COVID-19 IgG and IgM Antibody ELISA Kits
Erba MannheimCE-marked Enzyme Immunoassay (ELISA) kits for the detection of IgG and IgM antibodies to SARS-CoV-2 in human serum
Diagnostic Tests/Kits
CE-marked Enzyme Immunoassay (ELISA) kits for the detection of IgG and IgM antibodies to SARS-CoV-2 in human serum
The COVID-19 ImmunoRank™ Neutralization MICRO-ELISA test for detection of circulating SARS-CoV-2 neutralizing antibodies. The assay is designed to detect antibodies of all Ig classes in human plasma or serum that bind to the SARS-CoV-2 receptor binding domain (RBD) and are capable of blocking the binding of the RBD to angiotensin-converting enzyme 2 (ACE2), the viral entry receptor on the surface of target cells.
C083 Cellulose Fiber Sample Pad Sheets for use in lateral flow, assay development, lateral flow immunoassays, lateral flow assay devices & immunoassay IVDs
Rapid nucleic acid detection post isothermal amplification for decentralised, point of care molecular testing
Provides sensitive and specific measurements of antibodies against four SARS-CoV-2 proteins: nucleocapsid, receptor binding domain, spike 1, and spike 2 viral proteins.
Provides sensitive and specific quantitation of antibodies against four SARS-CoV-2 proteins: nucleocapsid, receptor binding domain, spike 1, and spike 2 viral proteins.
BioReady Gold Nanospheres - Bare (Citrate) - 40 nm, 20 OD in aqueous 0.02 mM sodium citrate
BioReady Gold Nanospheres - Bare (Citrate) - 80 nm, 20 OD in aqueous 0.02 mM sodium citrate
BioReady Gold Nanospheres - Streptavidin - 40 nm, 10 OD in aqueous conjugation buffer
BioReady Gold Nanoshells - Streptavidin - 150 nm, 10 OD in aqueous conjugation buffer
In children, luteinizing hormone, along with follicle-stimulating hormone, is used to diagnose delayed and precocious (early) puberty. This assay is sensitive to 0.009 mIU/mL and is more appropriate for use in children. This assay offers a 10-fold increase in analytical sensitivity over existing automated immunoassays.
In children, follicle-stimulating hormone along with luteinizing hormone, is used to diagnose delayed and precocious (early) puberty. This assay is sensitive to 0.02 IU/L and is more appropriate for use in children. This assay offers a 10-fold increase in analytical sensitivity over existing automated immunoassays.
Dried blood spot specimen stability makes it a practical alternative to venous blood. Instead of traveling to a clinic to get blood drawn, a blood spot sample can be taken at a convenient site and mailed to a laboratory. It opens new possibilities in testing, such as comparison of historical to current patient results; simplified blood sampling for patients in remote locations, for those who are homebound or those that pre…
The LIAISON® SARS-CoV-2 TrimericS IgG assay enables the reliable detection of Trimeric S spike protein IgG antibodies – the body’s natural defense response against SARS-CoV-2.

The LumiraDx D-Dimer Test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify D-Dimer levels in whole blood and plasma. It is the only direct fingerstick D-Dimer assay available today*, aiding healthcare professionals to exclude deep vein thrombosis (DVT) and pulmonary embolism (PE) in symptomatic patients with confidence** - in only 6 minutes.
The LumiraDx HbA1c test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify HbA1c in fingerstick and venous whole blood. Used with the LumiraDx Platform, the LumiraDx HbA1c test delivers rapid, reliable results in approximately < 7 minutes at the point of care.
The LumiraDx NT-proBNP test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify NT-proBNP in human capillary and venous whole blood and plasma samples (Lithium Heparin). Used with the LumiraDx Platform, the LumiraDx NT-proBNP test delivers rapid, reliable results in 12 minutes at the point of care.
The LumiraDx SARS-CoV-2 Ab Test is a microfluidic immunofluorescence assay for qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform the Test delivers rapid results at the point of care.
The LumiraDx SARS-CoV-2 Ag Test is a microfluidic immunofluorescence assay for the direct and qualitative detection of nucleocapsid protein antigen in nasal and nasopharyngeal swab specimens from individuals suspected of COVID-19 or asymptomatic individuals. Used with the LumiraDx Platform the test delivers rapid results at the point of care.
Lab-comparable results in just 5 minutes - With excellent performance and results in just 5 minutes, the LumiraDx SARS-CoV-2 Ag Ultra test enables you to accurately and confidently test more patients, optimize clinic workflows and help triage patients without delay